<DOC>
	<DOCNO>NCT02725541</DOCNO>
	<brief_summary>This open label , neoadjuvant phase II study evaluate objective response , toxicity , safety trastuzumab emtansine patient newly diagnose HER2-equivocal breast cancer . Trastuzumab emtansine dose 3.6 mg/kg intravenously administer every 3 week total 6 week . Patients achieve partial complete response 6-week treatment ( responder ) continue trastuzumab emtansine additional 12 week .</brief_summary>
	<brief_title>Trial Neoadjuvant Trastuzumab Emtansine Patients With HER2-Equivocal Breast Cancer</brief_title>
	<detailed_description>NATURE open label , neoadjuvant , phase II study design evaluate objective response rate trastuzumab emtansine patient newly diagnose HER2-equivocal breast cancer . Patients receive trastuzumab emtansine dose 3.6 mg/kg via intravenous infusion every 3 week total 6 week ( 2 21-day cycle ) . Patients achieve partial complete response ( responder ) 6-week treatment continue trastuzumab emtansine additional 12 week ( 4 cycle ) . The primary objective objective response rate 6 week neoadjuvant trastuzumab emtansine . Secondary objective include image response ( ultrasound magnetic resonance imaging ) six week neoadjuvant trastuzumab emtansine toxicity efficacy trastuzumab emtansine . After completion continue trastuzumab emtansine treatment , pathological complete response rate responder whole accord estrogen receptor status explore . Markers related mechanism action trastuzumab emtansine ( HER2 copy number circulate tumor cell ; tissue expression PTEN , PI3K , potential candidate marker ) also explore .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Female gender ; Age ≥18 year ; Eastern Cooperative Oncology Group performance status 01 ; Histologically confirm invasive breast cancer ; Primary tumor great equal 1 cm diameter , measure clinical examination mammography ultrasound ; Any N ; No evidence metastasis ( M0 ) ( isolated supraclavicular node involvement allow ) ; HER2 low equivocal status invasive component primary tumor ( confirmed central certify laboratory prior study entry ) HER2 low expression : 1+/2+ immunohistochemistry and/or HER2/CEP17 ratio &lt; 2.0 HER2 copy number &lt; 6.0 signals/cell HER2 equivocal expression : HER2 copy number ≥4.0 &lt; 6.0 signals/cell ; Hematopoietic status : Absolute neutrophil count ≥ 1.0 x 10^9/L , Platelet count ≥ 100 x 10^9/L , Hemoglobin least 9 g/dL ; • Hepatic status : Serum total bilirubin ≤1 x upper limit normal ( ULN ; In case know Gilbert 's syndrome , high serum total bilirubin [ &lt; 1.5 x ULN ] allow ) , Aspartate aminotransferase alanine aminotransferase ≤1.5 x ULN , Alkaline phosphatase ≤ 1.5 x ULN ; • Renal status : Creatinine ≤1.5 mg/dL ; International Normalized Ratio ≤1.5 x ULN ; Baseline leave ventricular ejection fraction ≥50 % , measure echocardiography multigated acquisition scan ; Negative serum urine βhuman chorionic gonadotropin pregnancy test within 7 day prior study entry patient childbearing potential . Women childbearing potential must use effective contraception ( barrier method [ condom , diaphragm ] conjunction spermicidal jelly , total abstinence . Oral , injectable , implantable hormonal contraceptive allow ) duration study least 7 month last dose study treatment ; Signed informed consent form ( ICF ) ; Patient accepts make available tumor sample submission central laboratory conduct translational study part protocol . Previous ( less 5 year ) current history malignant neoplasm , except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix ; Patients prior malignancy diagnose 5 year prior study entry ; Preexisting peripheral neuropathy ≥ grade 2 ; Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , transmural myocardial infarction , uncontrolled hypertension ( ≥180/110 ) , unstable diabetes mellitus , dyspnea rest , chronic oxygen therapy ; Concurrent disease condition would make patient inappropriate study participation serious medical disorder would interfere patient 's safety ; Unresolved unstable serious adverse event prior administration another investigational drug ; Dementia , alter mental status , psychiatric condition would prevent understand render ICF ; Concurrent neoadjuvant cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy trial therapy ) ; Concurrent treatment investigational agent participation another therapeutic clinical trial ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate trastuzumab emtansine component ; Ejection fraction &lt; 55 % low limit institutional normal range ; Pregnant lactate woman ; Concomitant use cytochrome P450 3A4 inhibitor inducer ; Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection , uncontrolled diabetes ) could cause unacceptable safety risk compromise compliance protocol ; Active infection require intravenous oral antibiotic ; Patients unwilling unable comply protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2 equivocal</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>Breast cancer</keyword>
</DOC>